IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 133 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,885,445 | -30.8% | 853,944 | +7.0% | 0.00% | 0.0% |
| Q2 2023 | $5,616,400 | +56.3% | 797,784 | +35.7% | 0.00% | 0.0% |
| Q1 2023 | $3,592,711 | -6.3% | 588,005 | -2.0% | 0.00% | 0.0% |
| Q4 2022 | $3,833,060 | -43.7% | 599,853 | -15.7% | 0.00% | -50.0% |
| Q3 2022 | $6,814,000 | -28.8% | 711,310 | -17.9% | 0.00% | 0.0% |
| Q2 2022 | $9,569,000 | -67.6% | 866,756 | -51.1% | 0.00% | -66.7% |
| Q1 2022 | $29,504,000 | -7.3% | 1,772,007 | +6.3% | 0.01% | 0.0% |
| Q4 2021 | $31,824,000 | -24.9% | 1,667,094 | -3.0% | 0.01% | -25.0% |
| Q3 2021 | $42,388,000 | -6.4% | 1,718,933 | -1.2% | 0.01% | -11.1% |
| Q2 2021 | $45,269,000 | -5.2% | 1,739,775 | +15.3% | 0.01% | -10.0% |
| Q1 2021 | $47,760,000 | -30.8% | 1,508,572 | +1.4% | 0.01% | -33.3% |
| Q4 2020 | $69,043,000 | +95.8% | 1,488,001 | +38.9% | 0.02% | +66.7% |
| Q3 2020 | $35,256,000 | +22.3% | 1,070,931 | +1.9% | 0.01% | +12.5% |
| Q2 2020 | $28,839,000 | +9.0% | 1,050,543 | +18.8% | 0.01% | -11.1% |
| Q1 2020 | $26,465,000 | +67.8% | 884,075 | +55.2% | 0.01% | +125.0% |
| Q4 2019 | $15,770,000 | +63.0% | 569,706 | +7.2% | 0.00% | +33.3% |
| Q3 2019 | $9,674,000 | -29.4% | 531,498 | -4.9% | 0.00% | -25.0% |
| Q2 2019 | $13,711,000 | +203.9% | 559,171 | +17.8% | 0.00% | +300.0% |
| Q1 2019 | $4,512,000 | +6.7% | 474,488 | -0.6% | 0.00% | 0.0% |
| Q4 2018 | $4,227,000 | +5.9% | 477,565 | +34.6% | 0.00% | 0.0% |
| Q3 2018 | $3,992,000 | -12.3% | 354,834 | -0.2% | 0.00% | 0.0% |
| Q2 2018 | $4,552,000 | -37.1% | 355,618 | -17.0% | 0.00% | -50.0% |
| Q1 2018 | $7,237,000 | +181.5% | 428,209 | +33.3% | 0.00% | +100.0% |
| Q4 2017 | $2,571,000 | +26.8% | 321,350 | +22.8% | 0.00% | 0.0% |
| Q3 2017 | $2,028,000 | +12.9% | 261,692 | +7.1% | 0.00% | 0.0% |
| Q2 2017 | $1,796,000 | – | 244,354 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |